Cat. No.: HY-B0069

Fludarabine

(Synonyms: F-ara-A; NSC 118218)

106 Cited Publications

고객리뷰

Based on 106 publication(s) in Google Scholar

Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.73%
CAS No.: 21679-14-1
화학식: C₁₀H₁₂FN₅O₄
분자량:285.24

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fludarabine Chemical Structure

CAS No.: 21679-14-1

사이즈

가격

재고

수량

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability 견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

대량구매 문의

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (106)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Bioz

Biological Activity

제품 설명

All DNA/RNA Synthesis Isoforms :

All STAT Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	47.44 μM Compound: fludarabine	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 20605656]
CCRF-CEM	IC₅₀	0.4 μM Compound: Table I Row 1	Compound was tested for cytotoxicity against CCRF-CEM cell lines Compound was tested for cytotoxicity against CCRF-CEM cell lines	[PMID: 1732556]
CCRF-CEM	IC₅₀	19.49 μM Compound: fludarabine	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 20605656]
HCT-116	IC₅₀	6.6 μM Compound: Fludarabine	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 25462277]
HCT-116	IC₅₀	8 μM Compound: Fludarabine	Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 29326016]
HCT-116	IC₅₀	8 μM Compound: Fludarabine	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
HCT-116	IC₅₀	8.3 μM Compound: Fludarabine	Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
HeLa	EC₅₀	16 μM Compound: Flu	Antitumor activity against human HeLa cells assessed as cell viability by MTT assay Antitumor activity against human HeLa cells assessed as cell viability by MTT assay	[PMID: 24673739]
Hep 3B2	IC₅₀	27.8 μM Compound: Fludarabine	Cytotoxicity against human Hep3B cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human Hep3B cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
Hep 3B2	IC₅₀	27.8 μM Compound: Fludarabine	Cytotoxicity against human Hep3B cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human Hep3B cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
HEp-2	IC₅₀	9 μM Compound: Table I Row 1	Compound was tested for cytotoxicity against HEp-2 cell lines Compound was tested for cytotoxicity against HEp-2 cell lines	[PMID: 1732556]
HepG2	IC₅₀	17 μM Compound: Fludarabine	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
HepG2	IC₅₀	17 μM Compound: Fludarabine	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
HepG2	IC₅₀	20 μM Compound: Fludarabine	Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay Antiproliferative activity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 29326016]
Huh-7	IC₅₀	24.4 μM Compound: Fludarabine	Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
Huh-7	IC₅₀	28.4 μM Compound: Fludarabine	Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
Huh-7	IC₅₀	30 μM Compound: Fludarabine	Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay Antiproliferative activity against human HuH7 cells after 72 hrs by SRB assay	[PMID: 29326016]
Huh-7	IC₅₀	60.1 μM Compound: Fludarabine	Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay Cytotoxicity against human HuH7 cells after 72 hrs by SRB assay	[PMID: 25462277]
JVM-2	EC₅₀	10.4 μM Compound: Flu	Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis Antitumor activity against human JVM2 cells assessed as cell viability after 48 hrs by FACS analysis	[PMID: 24673739]
K562	IC₅₀	0.15 μM Compound: Table I Row 1	Compound was tested for cytotoxicity against K562 cell lines Compound was tested for cytotoxicity against K562 cell lines	[PMID: 1732556]
K562	IC₅₀	0.26 μM Compound: fludarabine	Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay Cytotoxicity against human paclitaxel-resistant K562 cells after 72 hrs by MTT assay	[PMID: 20605656]
K562	IC₅₀	0.6 μg/mL Compound: Fludarabine	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay	[PMID: 12617912]
K562	IC₅₀	0.6 μg/mL Compound: Fludarabine	Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay	[PMID: 12617912]
K562	IC₅₀	267 μM Compound: fludarabine	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20605656]
L1210	IC₅₀	3 μM Compound: Table I Row 1	Compound was tested for cytotoxicity against L1210 cell lines Compound was tested for cytotoxicity against L1210 cell lines	[PMID: 1732556]
Mahlavu	IC₅₀	10 μM Compound: Fludarabine	Antiproliferative activity against human Mahlavu cells after 72 hrs by SRB assay Antiproliferative activity against human Mahlavu cells after 72 hrs by SRB assay	[PMID: 29326016]
Mahlavu	IC₅₀	14.2 μM Compound: Fludarabine	Cytotoxicity against human Mahlavu cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human Mahlavu cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
Mahlavu	IC₅₀	14.2 μM Compound: Fludarabine	Cytotoxicity against human Mahlavu cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human Mahlavu cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
MCF7	IC₅₀	15 μM Compound: Fludarabine	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29326016]
MCF7	IC₅₀	15.2 μM Compound: Fludarabine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
MCF7	IC₅₀	15.2 μM Compound: Fludarabine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
PBMC	IC₅₀	1.9 μM Compound: fludarabine	Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay	[PMID: 25562417]
PBMC	IC₅₀	10 μM Compound: fludarabine	Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells Cytotoxicity against patient PBMC after 48 hrs by CellTitre-Blue assay in presenc of mouse M210B4 cells	[PMID: 25562417]
PBMC	IC₅₀	14 μM Compound: fludarabine	Cytotoxicity against healthy human PBMC after 48 hrs by CellTitre-Blue assay Cytotoxicity against healthy human PBMC after 48 hrs by CellTitre-Blue assay	[PMID: 25562417]
PLC	IC₅₀	41.7 μM Compound: Fludarabine	Cytotoxicity against human PLC cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human PLC cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
PLC	IC₅₀	41.7 μM Compound: Fludarabine	Cytotoxicity against human PLC cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human PLC cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
SNU-182	IC₅₀	37.2 μM Compound: Fludarabine	Cytotoxicity against human SNU-182 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-182 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
SNU-182	IC₅₀	37.2 μM Compound: Fludarabine	Cytotoxicity against human SNU-182 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-182 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
SNU-387	IC₅₀	33.8 μM Compound: Fludarabine	Cytotoxicity against human SNU-387 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-387 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
SNU-387	IC₅₀	33.8 μM Compound: Fludarabine	Cytotoxicity against human SNU-387 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-387 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
SNU-398	IC₅₀	0.2 μM Compound: Fludarabine	Cytotoxicity against human SNU-398 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-398 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
SNU-398	IC₅₀	0.2 μM Compound: Fludarabine	Cytotoxicity against human SNU-398 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-398 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
SNU-423	IC₅₀	32.6 μM Compound: Fludarabine	Cytotoxicity against human SNU-423 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-423 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
SNU-423	IC₅₀	32.6 μM Compound: Fludarabine	Cytotoxicity against human SNU-423 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-423 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
SNU-449	IC₅₀	25.1 μM Compound: Fludarabine	Cytotoxicity against human SNU-449 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-449 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
SNU-449	IC₅₀	25.1 μM Compound: Fludarabine	Cytotoxicity against human SNU-449 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-449 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38688437]
SNU-475	IC₅₀	41.5 μM Compound: Fludarabine	Cytotoxicity against human SNU-475 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Cytotoxicity against human SNU-475 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 38107180]
SNU-475	IC₅₀	41.5 μM Compound: Fludarabine	Cytotoxicity against human SNU-475 cells assessed as cell growth inhibition by SRB assay Cytotoxicity against human SNU-475 cells assessed as cell growth inhibition by SRB assay	[PMID: 38688437]
T47D	IC₅₀	46.2 μM Compound: Fludarabine	Cytotoxicity against human T47D cells after 72 hrs by SRB assay Cytotoxicity against human T47D cells after 72 hrs by SRB assay	[PMID: 25462277]

In Vitro

Fludarabine (5 μM; 48 hours) induces a decrease in p27kip1 expression^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

B-CLL cells
Concentration:

5 μM
Incubation Time:

24 hours
Result:

Induces a decrease in p27kip1 expression. The decrease in p27kip1 expression was significantly correlated to the extent of in vitro apoptosis.

In Vivo

Fludarabine (0.8 mg/kg; i.p.; two cycles for 5 days every 2 weeks) in combination with Cyclophosphamide (400 mg/kg; i.p.; 2 weeks) decreases incidence of GVHD^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

F-1 mice received 105 BCL-1 leukemia cells^[6]
Dosage:

0.8 mg/kg
Administration:

Intraperitoneal injection; two cycles for 5 days every 2 weeks
Result:

Combination with Cyclophosphamide decreased incidence of graft-versus-host disease (GVHD).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 21679-14-1
Appearance Solid
분자량 285.24
화학식 C₁₀H₁₂FN₅O₄
Color White to yellow
SMILES

O[C@H]1[C@H](O)[C@H](N2C(N=C(F)N=C3N)=C3N=C2)O[C@@H]1CO
Synonyms

F-ara-A; NSC 118218
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (106)

All Flow CytometryWBRT-PCR

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Signal Transduct Target Ther

Oleic acid restores the impaired antitumor immunity of γδ-T cells induced by palmitic acid. [Abstract]

2025 Jul 3;10(1):209. PMID: 40603316
Cell Metab

Stress triggers irritable bowel syndrome with diarrhea through a spermidine-mediated decline in type I interferon. [Abstract]

2025 Jan 7;37(1):87-103.e10. PMID: 39366386

Fludarabine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Jan 7;37(1):87-103.e10. [Abstract]

Mouse smooth muscle cells were treated with PBS or IFN-α (1000U/ml), with or without Fludarabine (10μM) for 12 h. Quantitative PCR analysis of the mRNA expression of the indicated smooth muscle contraction genes.
Nat Neurosci

β2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer's disease model mice. [Abstract]

2023 Jul;26(7):1170-1184. PMID: 37264159
Cell Mol Immunol

Serine metabolism orchestrates macrophage polarization by regulating the IGF1-p38 axis. [Abstract]

2022 Nov;19(11):1263-1278. PMID: 36180780
Cell Host Microbe

Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. [Abstract]

2026 Feb 11;34(2):245-262.e8. PMID: 41605216
Nat Commun

Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma. [Abstract]

2026 Feb 28;17(1):3324. PMID: 41764166
Nat Commun

Injectable ECM-mimetic dynamic hydrogels abolish ferroptosis-induced post-discectomy herniation through delivering nucleus pulposus progenitor cell-derived exosomes. [Abstract]

2025 Apr 1;16(1):3131. PMID: 40169595
Nat Commun

Oxidative phosphorylation is a key feature of neonatal monocyte immunometabolism promoting myeloid differentiation after birth. [Abstract]

2025 Mar 6;16(1):2239. PMID: 40050264
Nat Commun

Glycolysis inhibition induces anti-tumor central memory CD8+T cell differentiation upon combination with microwave ablation therapy. [Abstract]

2024 May 31;15(1):4665. PMID: 38821965

Fludarabine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 May 31;15(1):4665. [Abstract]

Percentages of CD44hiCD62L+CD8+T cells in isolated CD8+T cells after coculturing with PBS + DMSO, PBS + fludarabine (flu; 5 μM),2DG + DMSO, or 2DG + fludarabine for 4 days.
Nat Commun

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer. [Abstract]

2023 Apr 13;14(1):2109. PMID: 37055410
Nat Commun

The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. [Abstract]

2021 Mar 29;12(1):1940. PMID: 33782411

Fludarabine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Mar 29;12(1):1940. [Abstract]

SW1990 cells transfected with indicated 20, 50 μM Fludara with 20 ng/mL IFN-γ for 24 hours, immunoblotting analyses are performed using the indicated antibodies.
Cell Death Differ

AARS1-mediated lactylation of H3K18 and STAT1 promotes ferroptosis in diabetic nephropathy. [Abstract]

2025 Sep 23. PMID: 40987895
Cell Death Differ

Cullin 4B-RING E3 ligase negatively regulates the immunosuppressive capacity of mesenchymal stem cells by suppressing iNOS. [Abstract]

2025 Jan;32(1):149-161. PMID: 39138375

Fludarabine purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2025 Jan;32(1):149-161. [Abstract]

The protein levels of iNOS, STAT1 and phosphorylated STAT1 in the Cul4 bdeficient and control MSCs treated with cytomix in the presence or absence of TGF-β1 (5 ng/ml) and/or fludarabine (15 μg/mL) for 24 h were detected by Western blotting.
Acta Pharm Sin B

STK39 inhibits antiviral immune response by inhibiting DCAF1-mediated PP2A degradation. [Abstract]

2025 Mar;15(3):1535-1551. PMID: 40370558
Adv Sci (Weinh)

Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model. [Abstract]

2025 Sep 23:e04569. PMID: 40985297
Adv Sci (Weinh)

PGRN Inhibits Early B-cell Activation and IgE Production Through the IFITM3-STAT1 Signaling Pathway in Asthma. [Abstract]

2024 Dec;11(45):e2403939. PMID: 39412083
Nat Chem Biol

Mutanofactin promotes adhesion and biofilm formation of cariogenic Streptococcus mutans. [Abstract]

2021 May;17(5):576-584. PMID: 33664521
J Exp Clin Cancer Res

Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway. [Abstract]

2019 Aug 22;38(1):370. PMID: 31438997

Fludarabine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 Aug 22;38(1):370. [Abstract]

Western blot of JAK2 and STAT1 phosphorylation and CXCL1 expression in cells pretreated with Fludarabine (100 μM) for 1 h and subsequently treated with VP-16 (20 μM) or CPT-11 (80 μg/mL) for 0.5 h.
Redox Biol

Glucose-6-phosphate dehydrogenase alleviates epileptic seizures by repressing reactive oxygen species production to promote signal transducer and activator of transcription 1-mediated N-methyl-d-aspartic acid receptors inhibition. [Abstract]

2024 Aug:74:103236. PMID: 38875958
J Infection

Interferon regulatory factor 1 eliminates mycobacteria by suppressing p70 S6 kinase via mechanistic target of rapamycin signaling. [Abstract]

2019 Sep;79(3):262-276. PMID: 31226272
Cell Rep Med

HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]

2026 Apr 21;7(4):102691. PMID: 41861828
Cell Rep Med

Interferon-driven CAF reprogramming augments immunogenic response to neoadjuvant radiotherapy in colorectal cancer. [Abstract]

2025 Aug 19;6(8):102251. PMID: 40730191
Pharmacol Res

Targeting Type I IFN/STAT1 signaling inhibited and reversed corneal squamous metaplasia in Aire-deficient mouse. [Abstract]

2023 Jan:187:106615. PMID: 36535573
J Neuroinflammation

IFN-γ signaling links ventriculomegaly to choroid plexus and ependyma dysfunction following maternal immune activation. [Abstract]

2025 Mar 15;22(1):83. PMID: 40089736
J Neuroinflammation

Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8+ T cells in cerebral malaria. [Abstract]

2024 May 7;21(1):119. PMID: 38715061
J Neuroinflammation

AXL kinase-mediated astrocytic phagocytosis modulates outcomes of traumatic brain injury. [Abstract]

2021 Jul 7;18(1):154. PMID: 34233703
Cell Death Dis

IL-27 disturbs lipid metabolism and restrains mitochondrial activity to inhibit γδ T17 cell-mediated skin inflammation. [Abstract]

2024 Jul 9;15(7):491. PMID: 38982043
Cell Death Dis

Novel roles of LSECtin in gastric cancer cell adhesion, migration, invasion, and lymphatic metastasis. [Abstract]

2022 Jul 11;13(7):593. PMID: 35821222
Genome Biol

Multi-omics approaches reveal that diffuse midline gliomas present altered DNA replication and are susceptible to replication stress therapy. [Abstract]

2024 Dec 20;25(1):319. PMID: 39707510
Cell Commun Signal

Targeting CCL2-CCR2 signaling pathway alleviates macrophage dysfunction in COPD via PI3K-AKT axis. [Abstract]

2024 Jul 17;22(1):364. PMID: 39014433
Phytomedicine

Geniposide attenuates influenza virus-induced pneumonia by regulating inflammatory cytokines production. Evidences to elucidate the followed pathway. [Abstract]

2024 Sep 8:135:156018. PMID: 39303507
Free Radic Biol Med

Exosomal CagA induces macrophage polarization and ferroptosis by JAK1-2/STAT1 signaling pathway in Helicobacter pylori-associated gastritis. [Abstract]

2025 Nov:239:91-103. PMID: 40706822
Apoptosis

GSDME-dependent astrocyte pyroptosis promotes the progression of neuroinflammation in experimental cerebral malaria. [Abstract]

2025 Aug 14. PMID: 40813537
Biomed Pharmacother

In vitro study of cold atmospheric plasma-activated liquids inhibits malignant melanoma by affecting macrophage polarization through the ROS/JAK2/STAT1 pathway. [Abstract]

2024 Jun:175:116657. PMID: 38688171
J Transl Med

Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils. [Abstract]

2023 Nov 18;21(1):832. PMID: 37980535
PLoS Biol

CMPK2 is a host restriction factor that inhibits infection of multiple coronaviruses in a cell-intrinsic manner. [Abstract]

2023 Mar 17;21(3):e3002039. PMID: 36930652
Cell Rep

Macrophage glycine transporter supports IL-1β production by modulating the AKT1/mTOR/NLRP3 pathway. [Abstract]

2026 Jan 3;45(1):116683. PMID: 41485223
Cell Rep

CD169+ macrophages identify and eliminate tumor cells in colorectal cancer through CD169/CD43 interaction and FasL-driven apoptosis. [Abstract]

2025 Sep 26;44(10):116351. PMID: 41016034
Cell Rep

ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. [Abstract]

2025 Sep 16;44(10):116314. PMID: 40966083
Cell Rep

Nuclear HMGB1 is critical for CD8 T cell IFN-γ production and anti-tumor immunity. [Abstract]

2024 Aug 7;43(8):114591. PMID: 39116204
Food Front

2023 Jun 10.
Antioxidants (Basel)

Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. [Abstract]

2026 Mar 25;15(4):413. PMID: 42072056
J Agric Food Chem

Diosmetin Ameliorates Nonalcoholic Steatohepatitis through Modulating Lipogenesis and Inflammatory Response in a STAT1/CXCL10-Dependent Manner. [Abstract]

2021 Jan 20;69(2):655-667. PMID: 33404223
JCI Insight

Deletion of SH2D5 alleviates epileptic seizures and NMDAR expression via autophagic degradation of STAT1. [Abstract]

2025 Aug 22;10(16):e191347. PMID: 40857409
JCI Insight

Klf9 promotes the repair of myocardial infarction by regulating macrophage recruitment and polarization. [Abstract]

2025 Apr 8:e187072. PMID: 40198141
Ecotoxicol Environ Saf

The critical role of SETDB1-mediated CCND1/PI3K/AKT pathway via p53-RS di-methylation at K370 in the proliferation of WRL68 cells induced by nicotine. [Abstract]

2024 Jul 5:282:116686. PMID: 38971100
Prog Neurobiol

DNMT3L promotes neural differentiation by enhancing STAT1 and STAT3 phosphorylation independent of DNA methylation. [Abstract]

2021 Jun:201:102028. PMID: 33636226
J Bone Miner Res

Acetyltransferases CBP/p300 control transcriptional switch of β-catenin and Stat1 promoting osteoblast differentiation. [Abstract]

2023 Dec;38(12):1885-1899. PMID: 37850815
J Ethnopharmacol

Cepharanthine relieves nonalcoholic steatohepatitis through inhibiting STAT1/CXCL10 axis-mediated lipogenesis and inflammatory responses. [Abstract]

2025 Feb 11:341:119358. PMID: 39805479
Chem Biol Interact

4-Hydroxybenzoic acid restrains Nlrp3 inflammasome priming and activation via disrupting PU.1 DNA binding activity and direct antioxidation. [Abstract]

2024 Dec 1:404:111262. PMID: 39389441
J Ethnopharmacol

Quercetin serves as the major component of Xiang-lian Pill to ameliorate ulcerative colitis via tipping the balance of STAT1/PPARγ and dictating the alternative activation of macrophage. [Abstract]

2023 Sep 15:313:116557. PMID: 37142141
Cells

Pathologic Th1-Treg Cells Exacerbate Acute Lung Injury and Lethality in Sepsis. [Abstract]

2026 Mar 14;15(6):521. PMID: 41892312
Cancer Gene Ther

Modified hTERT promoters-driven purine nucleoside phosphorylase-gene therapy in association with chemo- and targeted therapy in the context of ovarian cancer. [Abstract]

2025 Aug;32(8):843-853. PMID: 40579465
CNS Neurosci Ther

Microglial priming by IFN-γ involves STAT1-mediated activation of the NLRP3 inflammasome. [Abstract]

2024 Oct;30(10):e70061. PMID: 39392762
Int J Mol Sci

LPS Disrupts Endometrial Receptivity by Inhibiting STAT1 Phosphorylation in Sheep. [Abstract]

2024 Dec 21;25(24):13673. PMID: 39769435
PLoS Pathog

Suppressing neutrophil itaconate production attenuates Mycoplasma pneumoniae pneumonia. [Abstract]

2024 Nov 5;20(11):e1012614. PMID: 39499730
Int J Mol Sci

The Activation of Reticulophagy by ER Stress through the ATF4-MAP1LC3A-CCPG1 Pathway in Ovarian Granulosa Cells Is Linked to Apoptosis and Necroptosis. [Abstract]

2023 Feb 1;24(3):2749. PMID: 36769070
PLoS Pathog

IL-2-mTORC1 signaling coordinates the STAT1/T-bet axis to ensure Th1 cell differentiation and anti-bacterial immune response in fish. [Abstract]

2022 Oct 25;18(10):e1010913. PMID: 36282845
Int J Mol Sci

Different Signaling Pathways Define Different Interferon-Stimulated Gene Expression during Mycobacteria Infection in Macrophages. [Abstract]

2019 Feb 3;20(3). pii: E663. PMID: 30717477
Front Pharmacol

Strongylocentrotus nudus Eggs Polysaccharide Enhances Macrophage Phagocytosis Against E.coli Infection by TLR4/STAT3 Axis. [Abstract]

2022 Mar 17;13:807440. PMID: 35370674
Int Immunopharmacol

CGRP alleviates epilepsy via JAK1-STAT1-P2RX7 signaling: a novel neuroprotective axis targeting neuronal damage. [Abstract]

2025 Dec 21:170:116080. PMID: 41429063
Eur J Pharmacol

AMT inhibits the progression of non-small cell lung cancer by suppressing the PI3K/AKT/GSK-3β/β-catenin pathway via H3K27me3 regulation. [Abstract]

2026 Jan 12:1011:178460. PMID: 41354296
Eur J Pharmacol

Procyanidin B2 alleviates LPS-induced acute lung injury by regulating M1 macrophage polarization and inhibiting pyroptosis via the NF-κB/JAK2/STAT1 signaling pathway. [Abstract]

2025 Nov 5:1006:178149. PMID: 40975473
Int Immunopharmacol

Phenylacetaldehyde attenuates Cutibacterium acnes-induced inflammation in keratinocytes and monocytes. [Abstract]

2025 May 17:158:114885. PMID: 40383096
Int Immunopharmacol

House dust mite induced mucosal barrier dysfunction and type 2 inflammatory responses via the MAPK/AP-1/IL-24 Signaling pathway in allergic rhinitis. [Abstract]

2025 Jan 17:148:113972. PMID: 39826453
J Med Virol

Monkeypox Virus Is Inhibited by Nucleoside Analogues Including the Acyclic Phosphonates Adefovir and Tenofovir In Vitro. [Abstract]

2025 Nov;97(11):e70669. PMID: 41137742
Front Endocrinol

Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling. [Abstract]

2019 Jul 3:10:441. PMID: 31333586
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
J Infect Dis

NO-producing Polymorphonuclear Neutrophils Confer Protection against Chlamydia psittaci in Mouse Lung Infection. [Abstract]

2023 Aug 16;228(4):453-463. PMID: 36961856
FASEB J

STING Facilitates Vascular Calcification via p-STAT1/NLRP3 Signal. [Abstract]

2025 Apr 15;39(7):e70530. PMID: 40193045
FEBS J

Interferon-γ induces retinal pigment epithelial cell Ferroptosis by a JAK1-2/STAT1/SLC7A11 signaling pathway in Age-related Macular Degeneration. [Abstract]

2022 Apr;289(7):1968-1983. PMID: 34741776
Oncol Res

Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo. [Abstract]

2024 May 23;32(6):1109-1118. PMID: 38827326
iScience

SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. [Abstract]

2023 Jan 23;26(2):106027. PMID: 36818292
Antiviral Res

Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response. [Abstract]

2023 Sep:217:105676. PMID: 37481038
Front Mol Biosci

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway. [Abstract]

2021 Oct 22;8:652443. PMID: 34746227
Food Sci Nutr

Lycium barbarum Polysaccharide Alleviates Renal Damage in Mouse Sepsis by Regulating M1/M2 Macrophage Polarization. [Abstract]

2026 Feb 15;14(2):e71561. PMID: 41700132
ACS Infect Dis

Treponema pallidum Promotes the Polarization of M2 Subtype Macrophages to M1 Subtype Mediating the Apoptosis and Inhibiting the Angiogenesis of Human Umbilical Vein Endothelial Cells. [Abstract]

2023 Dec 8;9(12):2548-2559. PMID: 37983134
Cell Signal

A STAT1-GBP3-STING positive feedback loop governs inflammation, oxidative stress, and DNA damage to trigger acute aortic dissection. [Abstract]

2025 Nov:135:112015. PMID: 40714274
Cell Signal

Glioblastoma cells secrete ICAM1 via FASN signaling to promote glioma-associated macrophage infiltration. [Abstract]

2025 Apr 17:111823. PMID: 40252818
PLoS Genet

Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. [Abstract]

2024 May 28;20(5):e1011293. PMID: 38805570
J Immunol Res

2026 Jan 9.
Heliyon

Qingfei mixture mitigates immunosuppression of tumor microenvironment in non-small cell lung cancer by blocking stat1/Ido1-mediated tryptophan-kynurenine pathway. [Abstract]

2024 May 31;10(11):e32260. PMID: 38882349
Exp Cell Res

Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell activation by downregulating inflammation and apoptosis. [Abstract]

2021 Oct 15;407(2):112784. PMID: 34508746
Viruses

Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. [Abstract]

2021 Apr 27;13(5):774. PMID: 33925713
Phytochemistry

Potential HIV latency-reversing agents with STAT1-activating activity from the leaves of Wikstroemia chamaedaphne. [Abstract]

2022 Nov:203:113395. PMID: 36027969
Am J Physiol Gastrointest Liver Physiol

Antibiotics treatment promotes squamocolumnar junction tumor progression via tumor immune evasion in K19-Wnt1/C2mE mice fed high-fat diet and acidic bile salts. [Abstract]

2026 Jul 1;331(1):G38-G59. PMID: 42173516
J Cancer

Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis. [Abstract]

2024 May 5;15(11):3510-3530. PMID: 38817865
Mol Carcinog

POR overexpression induces tamoxifen-resistance in breast cancer through the STAT1/c-Myc pathway. [Abstract]

2023 Feb;62(2):249-260. PMID: 36321415
Kaohsiung J Med Sci

Activation of PPARγ regulates M1/M2 macrophage polarization and attenuates dextran sulfate sodium salt-induced inflammatory bowel disease via the STAT-1/STAT-6 pathway. [Abstract]

2024 Dec 30:e12927. PMID: 39737788
Front Biosci (Landmark Ed)

Cancer-Associated Fibroblasts in Gastric Cancer Regulate Macrophage Polarization through RCN3 Pathway. [Abstract]

2024 Aug 14;29(8):279. PMID: 39206893
Hereditas

An 8-gene predicting survival model of hepatocellular carcinoma (HCC) related to pyroptosis and cuproptosis. [Abstract]

2023 Jul 18;160(1):30. PMID: 37464443
Biochem Biophys Res Commun

Polyphyllin I enhances the anti-tumor efficacy of Palbociclib by reversing M2 macrophage polarization in lung cancer. [Abstract]

2025 Jun 18:777:152228. PMID: 40578288
Biochem Biophys Res Commun

Puerarin inhibits macrophage M1 polarization by combining STAT1 to reduce myocardial damage in EAM model mice. [Abstract]

2024 Sep 14:733:150702. PMID: 39298917
Iran J Immunol

JAK/STAT Signaling Pathway Mediates Anti-Tumor Immunity of CD8+ T Cells in Renal Cancer. [Abstract]

2024 Sep 25;21(3). PMID: 39319693
Authorea

2025 Oct 16.
bioRxiv

2025 Oct 27.
Res Sq

2025 Jul 17.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

2025 January 31.
Research Square Preprint

2023 Oct 9.
bioRxiv

2023 Jul 3.
Research Square Print

September 27th, 2022.
Ann Transl Med

Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells. [Abstract]

2020 Aug;8(15):951. PMID: 32953751
bioRxiv

2020 Apr.
Patent

US20160222465A1.

용액&용해도

In Vitro:

DMSO : 25 mg/mL (87.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5058 mL

17.5291 mL

35.0582 mL

5 mM

0.7012 mL

3.5058 mL

7.0116 mL

10 mM

0.3506 mL

1.7529 mL

3.5058 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (17.53 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Liang YB, et al. Downregulated SOCS1 expression activates the JAK1/STAT1 pathway and promotes polarization of macrophages into M1 type. Mol Med Rep. 2017 Nov;16(5):6405-6411. [Content Brief]

[2]. Sanhes L, et al. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. Leukemia. 2003 Jun;17(6):1104-11. [Content Brief]

[3]. Frank DA, et al. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5(4):444-447. [Content Brief]

[4]. Frank DA,et al. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999 Apr;5(4):444-7. [Content Brief]

[5]. Tournilhac O, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004 Jan 1;103(1):363-5. Epub 2003 Sep 11. [Content Brief]

[6]. Weiss L, et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintainseffective graft-versus-leukemia effect after allogeneic stem cell transplantation in murinelymphocytic leukemia. Bone Marrow Transplant. 2003 Jan;31(1):11-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5058 mL	17.5291 mL	35.0582 mL	87.6455 mL
	5 mM	0.7012 mL	3.5058 mL	7.0116 mL	17.5291 mL
	10 mM	0.3506 mL	1.7529 mL	3.5058 mL	8.7645 mL
	15 mM	0.2337 mL	1.1686 mL	2.3372 mL	5.8430 mL
	20 mM	0.1753 mL	0.8765 mL	1.7529 mL	4.3823 mL
	25 mM	0.1402 mL	0.7012 mL	1.4023 mL	3.5058 mL
	30 mM	0.1169 mL	0.5843 mL	1.1686 mL	2.9215 mL
	40 mM	0.0876 mL	0.4382 mL	0.8765 mL	2.1911 mL
	50 mM	0.0701 mL	0.3506 mL	0.7012 mL	1.7529 mL
	60 mM	0.0584 mL	0.2922 mL	0.5843 mL	1.4608 mL
	80 mM	0.0438 mL	0.2191 mL	0.4382 mL	1.0956 mL

Keywords

Fludarabine

106 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Fludarabine

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Rare Diseases Drug Library

Pediatric Drug Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Nephrotoxicity Compound Library

FDA Kinase Inhibitor Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Fludarabine

All DNA/RNA Synthesis Isoforms

All STAT Isoforms

Biological Activity

Chemical Information

Publications (106)

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Fludarabine Related Classifications

Cat. No.: HY-B0069